Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Isidori

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Cancers|March 29, 2023
Use of Next Generation Sequencing to Define the Origin of Primary MyelofibrosisGiuseppe Visani, Maryam Etebari, Fabio Fuligni, et al.
Cancers|June 23, 2018
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven ApproachAlessandro Isidori, Federica Loscocco, Marilena Ciciarello, et al.
Mediterranean Journal of Hematology and Infectious Diseases|December 4, 2012
Autologous stem cell transplantation for aggressive lymphomasGiuseppe Visani, Paola Picardi, Patrizia Tosi, et al.
Experimental Hematology|December 13, 2005
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cellsAntonio Curti, Simona Pandolfi, Michela Aluigi, et al.
Expert Review of Hematology|August 23, 2021
Safety of FLT3 inhibitors in patients with acute myeloid leukemiaClaudio Cerchione, Andrés Peleteiro Raíndo, Adrián Mosquera Orgueira, et al.
Leukemia & Lymphoma|June 24, 2008
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot studyGiuseppe Visani, Felicetto Ferrara, Francesco Alesiani, et al.
Expert Review of Hematology|September 18, 2014
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatmentAlessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, et al.
Leukemia & Lymphoma|September 14, 2004
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?Giuseppe Visani, Alessandro Isidori, Tiziana Grafone, et al.
Leukemia Research|October 9, 2017
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II studyGiuseppe Visani, Felicetto Ferrara, Francesco Di Raimondo, et al.
Blood|April 26, 2003
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilizationRoberto M Lemoli, Antonio de Vivo, Daniela Damiani, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Cancers|March 29, 2023
Use of Next Generation Sequencing to Define the Origin of Primary MyelofibrosisGiuseppe Visani, Maryam Etebari, Fabio Fuligni, et al.
Cancers|June 23, 2018
Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven ApproachAlessandro Isidori, Federica Loscocco, Marilena Ciciarello, et al.
Mediterranean Journal of Hematology and Infectious Diseases|December 4, 2012
Autologous stem cell transplantation for aggressive lymphomasGiuseppe Visani, Paola Picardi, Patrizia Tosi, et al.
Experimental Hematology|December 13, 2005
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cellsAntonio Curti, Simona Pandolfi, Michela Aluigi, et al.
Expert Review of Hematology|August 23, 2021
Safety of FLT3 inhibitors in patients with acute myeloid leukemiaClaudio Cerchione, Andrés Peleteiro Raíndo, Adrián Mosquera Orgueira, et al.
Leukemia & Lymphoma|June 24, 2008
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot studyGiuseppe Visani, Felicetto Ferrara, Francesco Alesiani, et al.
Expert Review of Hematology|September 18, 2014
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatmentAlessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, et al.
Leukemia & Lymphoma|September 14, 2004
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?Giuseppe Visani, Alessandro Isidori, Tiziana Grafone, et al.
Leukemia Research|October 9, 2017
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II studyGiuseppe Visani, Felicetto Ferrara, Francesco Di Raimondo, et al.
Blood|April 26, 2003
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilizationRoberto M Lemoli, Antonio de Vivo, Daniela Damiani, et al.
Pageof 9